ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

OBLN Obalon Therapeutics Inc

3.05
0.00 (0.00%)
After Hours
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Obalon Therapeutics Inc NASDAQ:OBLN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.05 2.81 2.87 0 01:00:00

Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)

26/07/2019 11:04am

Edgar (US Regulatory)



Issuer Free Writing Prospectus dated July 25, 2019
Filed Pursuant to Rule 433 under the Securities Act of 1933
Relating to the Preliminary Prospectus dated July 25, 2019
Registration Statement No. 333-232276

OBALON THERAPEUTICS, INC.

This free writing prospectus relates to, and should be read together with, the preliminary prospectus dated July 25, 2019 (the “Preliminary Prospectus”) included in Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-232276) (the “Registration Statement”) relating to a public offering of the common stock, and pre-funded warrants to purchase common stock, of Obalon Therapeutics, Inc. (the “Company”).

The Company has filed a registration statement (including a prospectus) with the Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates. Before you invest, you should read the prospectus in Registration Statement and other documents the Company has filed with the SEC for more complete information about the Company and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the Company, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by email at prospectus@alliancecg.com .







S1OBALONINVESTORPRESENTA001.JPG





S1OBALONINVESTORPRESENTA002.JPG





S1OBALONINVESTORPRESENTA003.JPG





S1OBALONINVESTORPRESENTA004.JPG





S1OBALONINVESTORPRESENTA005.JPG





S1OBALONINVESTORPRESENTA006.JPG





S1OBALONINVESTORPRESENTA007.JPG





S1OBALONINVESTORPRESENTA008.JPG





S1OBALONINVESTORPRESENTA009.JPG





S1OBALONINVESTORPRESENTA010.JPG





S1OBALONINVESTORPRESENTA011.JPG





S1OBALONINVESTORPRESENTA012.JPG





S1OBALONINVESTORPRESENTA013.JPG





S1OBALONINVESTORPRESENTA014.JPG





S1OBALONINVESTORPRESENTA015.JPG





S1OBALONINVESTORPRESENTA016.JPG





S1OBALONINVESTORPRESENTA017.JPG





S1OBALONINVESTORPRESENTA018.JPG





S1OBALONINVESTORPRESENTA019.JPG





S1OBALONINVESTORPRESENTA020.JPG





S1OBALONINVESTORPRESENTA021.JPG





S1OBALONINVESTORPRESENTA022.JPG





S1OBALONINVESTORPRESENTA023.JPG





S1OBALONINVESTORPRESENTA024.JPG





S1OBALONINVESTORPRESENTA025.JPG



1 Year Obalon Therapeutics Chart

1 Year Obalon Therapeutics Chart

1 Month Obalon Therapeutics Chart

1 Month Obalon Therapeutics Chart

Your Recent History

Delayed Upgrade Clock